Telephone

Telephone
+390289450270

Linkedin

Linkedin
Twin Helix

English

Language
English Italian English

Twin Helix

Covid 19 Fighting Area

Covid 19 Fighting Area

At this unprecedented moment in time
Twin Helix is firmly committed to serving customers, the scientific community and anyone who needs our capabilities.

Discover more

While the coronavirus pandemic (COVID-19) continues to evolve globally, many of us have inevitably been affected in our daily lives.
At this unprecedented time, full of challenges and uncertainties, Twin Helix is firmly committed to serving customers, the scientific community and anyone who needs our capabilities.
Using a unique HD-293 high-density mammalian expression system, GenScript is able to produce gram level proteins, which have been proven to work with ELISA tests. of clinical samples !

Covid 19 fighting area

Functional Spike Protein 2019-nCoV (RBD) for COVID-19 research

Name Application Purity QC
S protein (RBD) mFc IgM/lgG kit with Anti-Mouse antibody > 90% SDS-PAGE, WB, ELISA binding against ACE-2
S protein (RBD) His IgM/lgG kit with Anti-His antibody > 90% SDS-PAGE, WB, ELISA binding against ACE-2

Promising Antiviral Agents

Based on the above virtual screening results, and combined with the recent clinical reports, we have also obtained some valuable potential drugs for SARS-CoV-2, which can reduce drug development cycle by using drug relocation strategy.

Compound Information Condition
Darunavir Darunavir is an HIV protease inhibitor that is used in the treatment of AIDS and HIV infections. FDA Approved
Remdesivir Remdesivir is a nucleoside analogue, with effective antiviral activity (EC50 of 74 nM for SARS-CoV and MERS-CoV in HAE cells) Clinical
Camostat mesilate Camostat is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function. Approved/Preclinical
Baricitinib Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. FDA Approved
Favipiravir Favipiravir (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections. Approved/Preclinical
Ribavirin Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. FDA Approved
Chloroquine diphosphate Chloroquine is an aminoquinoline antimalarial and also is widely used as an autophagy inhibitor. Chloroquine also is an inhibitor of toll-like receptors (TLRs). FDA Approved
Nitazoxanide Nitazoxanide is a synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction. FDA Approved

COVID-19 / SARS-CoV-2 Compound Library

All screening collections in this category were designed to meet the requirements from global scientific research institutions and pharmaceutical companies to help speed up anti-COVID-19 drugs development. The compound libraries contain compounds that have been demonstrated to have anti-coronavirus activity or are broad-spectrum antiviral agents and compounds from virtual screening hits based on molecular docking with high affinity to 7 SARS-CoV-2 protein targets and 1 human ACE2.

Library Information CAT No
Anti-COVID-19 Compound Library A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents. L1710
Anti-COVID-19 compound library (CADD) A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1711
3CLpro-Targeted compound library (CADD) A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1712
ACE2-Targeted compound library (CADD) A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1713
RBD-Targeted compound library (CADD) A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1714
nsp16-Targeted compound library (CADD) A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1715
PLpro-Targeted compound library (CADD) A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1716
RdRP-Targeted compound library (CADD) A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1717
X Domain-Targeted compound library (CADD) A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1718
nsp15-Targeted compound library (CADD) A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening L1719
Anti-COVID-19 Traditional Chinese Medicine Compound Library A unique collection of 389 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening L6720

Rapid Nasal swab Antigene COVID 19

mass screening and tracking

While the coronavirus pandemic (COVID-19) continues to evolve globally, many of us have inevitably been affected in our daily lives.

The numbers in Italy and around the world unfortunately continue to grow, we are all waiting for the arrival of a new vaccine, but, for the next few months, we will still have to be very patient.

In the meantime, the only way to protect ourselves, is to track the contagions by proceeding as far as possible with mass screening, the scientific community in recent months has collected a huge amount of experience and, based on it, we focus on possible solutions in the field of rapid diagnostics.

Translated with www.DeepL.com/Translator (free version)

Fast, Easy, Safe

15 minutes to result

The new rapid test for COVID19 antigen is 35% more sensitive than traditional IgG/IgM immunoglobulin detection kits, requires no instrumentation and the swab is very gentle during the test on the patient, in fact just insert it in the nostrils for only 2, 5 cm deep and the results will be ready in about 15 minutes, making it a valuable tool for mass screening in different contexts such as schools, airports, ports and in all those contexts where tracking and control are essential to prevent the virus from spreading further within national borders.

 

Blot analysis of RBD Protein (His tag)

SDS-PAGE & Western blot Analysis

  • Lane M1: Protein Marker, GenScript, Cat. No. M00516
  • Lane M2: Protein Marker, GenScript, Cat. No M00521
  • Lane 1: BSA(2.00µg)
  • Lane 2: RBD Protein (Reducing condition, 2.00 µg)
  • Lane 3: RBD Protein (Non-reducing condition, 2.00 µg)
  • Lane 4: RBD Protein (Reducing condition)
  • Lane 5: RBD Protein (Non-reducing condition)
  • Primary antibody: Mouse-anti-His mAb (GenScript, Cat.No. A00186)

NCP-RBD-His binding Test

ELISA Results Binding against ACE2


© COPYRIGHT 2020 TWIN HELIX C.F. /P.IVA and n° Registro Imprese di Milano 05819650960 – REA Milano 1851394 Cap.Soc.Euro 50.000 i.v. - Società uninominale